Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a...
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is undervalued on EV/EBITDA.
Target Price
The average target price of PASG is 37 and suggests 193% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell